This week in PLoS Medicine: Six-gene predictor in pancreatic cancer treatment; Reviews for devices; Evidence-based policy in Africa

Image credit: George Gastin

Three new articles were published this week in PLoS Medicine: Jen Jen Yeh and colleagues developed and validated a six-gene signature in patients with pancreatic ductal adenocarcinoma that may be used to better stage the disease in these patients and assist in treatment decisions.

Using examples from recent FDA regulatory proceedings, Jonas Hines and colleagues critique the medical device premarket review and identify eight weaknesses in the process that should be remedied.

Lastly, as part of our continuing series on maternal, neonatal, and child health in sub-Saharan Africa, Igor Rudan and colleagues discuss various priority-setting tools for health care and research that can help develop evidence-based policy. See the earlier blog about the series with all articles which lists all the articles as they are published.

Remember you can comment on, annotate and rate any PLoS Medicine article and see the views, citations and other indications of impact of an article on that articles metrics tab.

This entry was posted in General, PLoS Medicine Week by Week and tagged , , . Bookmark the permalink.

Comments are closed.